A trapping ligand antagonist peptide H22-LP inhibition of human cytomegalovirus infection

作者：Shi, Wenjun; Xu, Bo; Tian, Peng; Li, Xiuying; Sun, Hanxiao^*

来源：Journal of Microbiology, Immunology, and Infection, 2016, 49(2): 189-195.

DOI：10.1016/j.jmii.2014.06.010

• human cytomegalovirus
• peptide
• viral G-protein-coupled receptor
• viral replication

Background: Human cytomegalovirus (HCMV) can cause acute or chronic diseases, especially in immunocompromised patients. Currently, most drugs licensed for the treatment of the herpes virus are nucleoside analogs that have been developed over the past 25 years. Drug resistance, development of drug related toxicity, and side effects limit their clinical use in patients. In a previous study, we found a trapping ligand H22-LP (the conservative sequence is NAHCALL) from a random phage library according to the broad-spectrum trapping receptor H22, which derived from the residue 14-35 near the N-terminal region of receptor US28 on HCMV. Here, the aim was to evaluate the anti-HCMV activity of H22-LP.
Methods: Antivirus activity of H22-LP on HCMV replication was visualized by fluorescence microscopy. We determined the effects of H22-LP on the expressions of HCMV late protein using q-PCR and Western blot. Comprehensive analysis of the characteristics of H22LP-mediated inhibition of HCMV were quantitatively analyzed by flow cytometry.
Results: H22-LP showed a 65.4% inhibition of viral infection at a concentration of 10 ng, and 50% inhibition at concentrations of 5 ng. The levels of mRNA and proteins were also found to have decreased by H22-LP in a concentration-dependent manner. The mode of antiviral action is based on a block of viral entry cells during HCMV cell adsorption/entry.
Conclusion: These results demonstrated that H22-LP could inhibit HCMV by direct interaction with the viral particle.

• 出版日期2016-4
• 单位暨南大学